Summary & Overview
HCPCS Level II J7332: Hyaluronan (triluron) Intra-articular Injection, 1 mg
HCPCS Level II code J7332 identifies a unit of hyaluronan or derivative, triluron, for intra-articular injection, 1 mg. This product is administered directly into joints to provide viscoelastic supplementation and symptom relief for degenerative joint conditions. Nationally, injectable hyaluronans are an important non-surgical intervention in managing joint pain and preserving function, with implications for outpatient utilization and pharmacy-benefit versus medical-benefit billing.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, expected sites of service, and common billing considerations. The publication provides benchmarks where available, summarizes relevant policy and coverage trends affecting reimbursement for intra-articular hyaluronan products, and outlines coding and billing contexts commonly encountered by clinicians and billing staff.
This summary is written for a national audience and is intended to clarify what J7332 represents, the clinical setting in which it is used, and the types of payer policies and administrative issues that influence coverage and billing practices.
Billing Code Overview
HCPCS Level II code J7332 represents hyaluronan or derivative, triluron, for intra-articular injection, 1 mg. This medication is used for intra-articular (within the joint) administration to treat joint conditions, typically osteoarthritis-related pain and joint lubrication.
Service type: Intra-articular injectable medication
Typical site of service: Outpatient clinic or physician office, ambulatory surgery center, or hospital outpatient department for joint injection procedures
Clinical & Coding Specifications
Clinical Context
A typical patient is a 60-year-old ambulatory adult with symptomatic osteoarthritis of the knee who has persistent joint pain and functional limitation after conservative therapy (oral analgesics, physical therapy, activity modification). The patient presents to an orthopedic clinic or ambulatory surgical center for an intra-articular viscosupplementation visit. The clinician confirms an indication for hyaluronan derivative injection, obtains informed consent, performs standard pre-procedure assessment including allergy review and anticoagulation reconciliation, cleans the knee, and uses landmark or ultrasound guidance to administer J7332 (hyaluronan or derivative, triluron, for intra-articular injection, 1 mg) into the affected joint. Post-procedure monitoring occurs onsite for a brief period for adverse reaction observation, and discharge instructions include activity modification and signs of infection or acute reaction. Typical sites of service are outpatient clinic, physician office, ambulatory surgical center, or occasionally emergency department for urgent joint pain management. The clinical workflow commonly includes evaluation visits, medication administration under aseptic technique, documentation of lot number and units administered, and billing for the product using J7332 with appropriate modifier(s) to indicate laterality, partial administration, or special circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |